Department of Infectious Disease and Clinical Microbiology
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- COVID-19, Cytomegalovirus (CMV), Tocilizumab, Anakinra, Mortality
- Sponsor
- Ramazan Gozukucuk
- Enrollment
- 167
- Locations
- 1
- Primary Endpoint
- The relationship between CMV reactivation and anti-cytokine treatment
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
The risk of secondary infection is high in critical patients hospitalized with the diagnosis of COVID-19. Immunosuppressive treatments are commonly used in critical COVID-19 patients, and immune dysfunction and CMV reactivation can be unnoticed in these patients.
Detailed Description
The records of critical patients were reviewed retrospectively. Whether these patients used tocilizumab and/or anakinra and their relationship with CMV reactivation were examined. Furthermore, the relationship between CMV reactivation and mortality and anti-cytokine treatment in patients was also examined. A total of 167 critical COVID-19 patients were included in the study, of which 38 (22.7%) were found to be CMV DNA positive. CMV positivity in patients treated with anti-cytokines (31.11%) was found to be significantly higher than in patients who were not treated with it (16.88%) (p:0.033). There was no significant difference in viral load levels (p:0.513). Furthermore, it was determined that anti-cytokine treatment significantly decreased mortality (p: 0.003) and that there was no significant relationship between CMV reactivation and mortality (p: 0.399). Even though CMV reactivation was high in critical COVID-19 patients who received anti-cytokine treatment, positive developments in morbidity and mortality were observed with early diagnosis and effective treatment.
Investigators
Ramazan Gozukucuk
Assos Prof Dr
Hisar Intercontinental Hospital
Eligibility Criteria
Inclusion Criteria
- •Critically ill patients over the age of 18 diagnosed with COVID-19 and patients followed in the intensive care unit.
Exclusion Criteria
- •Patients under the age of 18 with a mild/moderate course of COVID-19,
- •CMV PCR positive before anti-cytokine treatment,
- •patients who underwent hematopoietic stem cell transplantation
Outcomes
Primary Outcomes
The relationship between CMV reactivation and anti-cytokine treatment
Time Frame: 2020-2021
CMV positivity was found to be significantly higher in who receive anti-cytokine treatment